Public Production of Medicines and HIV/AIDS Activists: New Actors in the Generic Drug Regulatory Process
This chapter turns now to assess the stakeholders that question the current architecture of the pharmaceutical regulation in Brazil. There is an increasing apprehension among AIDS activists about the stringency of Brazil’s regulation for generic medicines, citing that these rules might limit competition and undermine access to medicines. Similarly, public pharmaceutical factories have voiced their struggle to adapt to this norm for different reasons and questioned the necessity of such strict regulation. The first section analyses the effects of generic drug regulation on the public production of medicines. This also serves as background information to the following section that assesses AIDS activists’ preferences and demands.